Axworthy DB - Search Results

1

Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.

Subbiah K, Hamlin DK, Pagel JM, Wilbur DS, Meyer DL, Axworthy DB, Mallett RW, Theodore LJ, Stayton PS, Press OW. Subbiah K, et al. Among authors: axworthy db. J Nucl Med. 2003 Mar;44(3):437-45. J Nucl Med. 2003. PMID: 12621012 Free article.

2

Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.

Hamblett KJ, Press OW, Meyer DL, Hamlin DK, Axworthy D, Wilbur DS, Stayton PS. Hamblett KJ, et al. Bioconjug Chem. 2005 Jan-Feb;16(1):131-8. doi: 10.1021/bc034049g. Bioconjug Chem. 2005. PMID: 15656584

3

Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas.

Pantelias A, Pagel JM, Hedin N, Saganic L, Wilbur S, Hamlin DK, Wilbur DS, Lin Y, Stone D, Axworthy D, Gopal AK, Press OW. Pantelias A, et al. Blood. 2007 Jun 1;109(11):4980-7. doi: 10.1182/blood-2006-11-056895. Epub 2007 Feb 15. Blood. 2007. PMID: 17303693 Free PMC article.

4

Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.

Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, Theodore LJ, Wilbur DS, Matthews DC, Press OW. Pagel JM, et al. Blood. 2003 Mar 15;101(6):2340-8. doi: 10.1182/blood-2002-03-0874. Epub 2002 Nov 21. Blood. 2003. PMID: 12446461 Free article.

5

Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.

Pagel JM, Lin Y, Hedin N, Pantelias A, Axworthy D, Stone D, Hamlin DK, Wilbur DS, Press OW. Pagel JM, et al. Blood. 2006 Jul 1;108(1):328-36. doi: 10.1182/blood-2005-11-4327. Epub 2006 Mar 23. Blood. 2006. PMID: 16556891 Free PMC article.

6

A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.

Lin Y, Pagel JM, Axworthy D, Pantelias A, Hedin N, Press OW. Lin Y, et al. Cancer Res. 2006 Apr 1;66(7):3884-92. doi: 10.1158/0008-5472.CAN-05-3443. Cancer Res. 2006. PMID: 16585217

7

Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.

Pagel JM, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y, Axworthy D, Hamlin DK, Wilbur DS, Gopal AK, Press OW. Pagel JM, et al. Cancer Res. 2007 Jun 15;67(12):5921-8. doi: 10.1158/0008-5472.CAN-07-0080. Cancer Res. 2007. PMID: 17575162

8

In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.

Lewis MR, Wang M, Axworthy DB, Theodore LJ, Mallet RW, Fritzberg AR, Welch MJ, Anderson CJ. Lewis MR, et al. Among authors: axworthy db. J Nucl Med. 2003 Aug;44(8):1284-92. J Nucl Med. 2003. PMID: 12902420 Free article.

9

Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein.

Sato N, Hassan R, Axworthy DB, Wong KJ, Yu S, Theodore LJ, Lin Y, Park L, Brechbiel MW, Pastan I, Paik CH, Carrasquillo JA. Sato N, et al. Among authors: axworthy db. J Nucl Med. 2005 Jul;46(7):1201-9. J Nucl Med. 2005. PMID: 16000290 Free article.

10

A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts.

Press OW, Corcoran M, Subbiah K, Hamlin DK, Wilbur DS, Johnson T, Theodore L, Yau E, Mallett R, Meyer DL, Axworthy D. Press OW, et al. Blood. 2001 Oct 15;98(8):2535-43. doi: 10.1182/blood.v98.8.2535. Blood. 2001. PMID: 11588052 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

40 results

Search Page

Filters